Clinical Trial Update: ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigates whether using ctDNA-minimal residual disease status to guide escalation of Ivonescimab plus Docetaxel in advanced non-smal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Second Xiangya Hospital of Central South University | Conditions: Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs) | Phase 2 | Status: RECRUITING